Savara Inc. (SVRA) Stock Analysis & Investment Frameworks
Savara Inc. (SVRA) stock analysis on Invetso. Review Savara Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Savara Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Savara Inc. Key Financial Metrics
- Market Cap: $867.04M
- Revenue: $N/A
- ROE: -90.28%
- ROIC: -82.30%
- Dividend Yield: N/A
About Savara Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Savara Inc. Investment Frameworks
Invetso analyzes Savara Inc. (SVRA) across the following frameworks:
- Savara Inc. 10Y Growth Potential
- Savara Inc. Scenario Analysis
- Savara Inc. Risks & Opportunities
- Savara Inc. Economic Moat
- Savara Inc. Business Model
- Savara Inc. Management
- Savara Inc. SWOT Analysis
- Savara Inc. Porter's 5 Forces
- Savara Inc. PESTLE Analysis
- Savara Inc. ESG Analysis